Study Detail

PHOSP-COVID

Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID)

Status: Open

Type: Observational

Funder:

Sponsor: University of Leicester

CI: Prof Chris Brightling

IRAS-Number: 285439

CPMS-ID: 46443

Approval Date: 01 July 2020

Summary:

The COVID-19 pandemic has had a major impact on the UK's health, social care andneconomy. The long-term sequelae of COVID-19 after discharge from hospital in both those with and without comorbidities are unknown. A comprehensive patient-centred holistic study is required to determine the chronic health and health economic sequelae of COVID-19 infection in post-hospitalisation survivors. This will define demographic, clinical and molecular biomarkers of the susceptibility and inform our understanding of the impact of interventions during the acute illness. These insights will guide consequent in-depth studies to inform precision medicine in at risk groups by directing new clinical trials and care for current and future post-COVID-19 patients. This study has been approved as part of the NIHR Urgent Public Health review. The study shall recruit individuals post-hospitalisation with a COVID-19 discharge diagnosis to study the short (0-3 months), medium (3-6 months) and long (6-12 months) effects of the disease. The study will analyse routine clinical data with linkage to retrospective and prospective health and social care records (Tier 1), enhanced clinical data and research-specific biosampling (Tier 2) and re-call of participants by genotype and phenotype for more detailed studies (Tier 3). Tier 2 participants for whom further clinical assessments are recommended may also be asked to provide additional samples and data (Tier 2 research) and will have their records extracted from those time-points. The study will recruit 10000 individuals with a minimum of 4000 in Tier 2. The study will continue to link to participants clinical data for at least 25 years or until the patient has deceased or withdrawn consent. The clinical study is underpinned by world-leading Universities, NIHR infrastructure e.g. BRCs, TRCs, CRFs and ARCs and the NHS. The study will take place in state-of-the-art facilities within our worldleading academic institutions and hospitals within the UK.

Description:

The COVID-19 pandemic has had a major impact on the UK's health, social care and economy. The long-term sequelae of COVID-19 after discharge from hospital in both those with and without comorbidities are unknown. A comprehensive patient-centred holistic study is required to determine the chronic health and health economic sequelae of COVID-19 infection in post-hospitalisation survivors. This will define demographic, clinical and molecular biomarkers of the susceptibility and inform our understanding of the impact of interventions during the acute illness. These insights will guide consequent in-depth studies to inform precision medicine in at risk groups by directing new clinical trials and care for current and future post-COVID-19 patients. This study has been approved as part of the NIHR Urgent Public Health review. The study shall recruit individuals post-hospitalisation with a COVID-19 discharge diagnosis to study the short (0-3 months), medium (3-6 months) and long (6-12 months) effects of the disease. The study will analyse routine clinical data with linkage to retrospective and prospective health and social care records (Tier 1), enhanced clinical data and research-specific biosampling (Tier 2) and re-call of participants by genotype and phenotype for more detailed studies (Tier 3). Tier 2 participants for whom further clinical assessments are recommended may also be asked to provide additional samples and data (Tier 2 research) and will have their records extracted from those time-points. The study will recruit 10000 individuals with a minimum of 4000 in Tier 2. The study will continue to link to participants clinical data for at least 25 years or until the patient has deceased or withdrawn consent. The clinical study is underpinned by world-leading Universities, NIHR infrastructure e.g. BRCs, TRCs, CRFs and ARCs and the NHS. The study will take place in state-of-the-art facilities within our worldleading academic institutions and hospitals within the UK.

Study URL:

https://www.phosp.org/

Back to listing